Display options
Share it on

Leuk Suppl. 2012 Aug;1:S5-6. doi: 10.1038/leusup.2012.6. Epub 2012 Aug 09.

Modern therapy of young and adult Ph-ALL.

Leukemia supplements

R Bassan, T Intermesoli, O Spinelli, E Oldani, A Rambaldi

Affiliations

  1. UOC Ematologia, Ospedale dell'Angelo e Ospedale SS , Giovanni e Paolo, Mestre-Venezia, Italy.
  2. UOC Ematologia, Ospedali Riuniti , Bergamo, Italy.

PMID: 27175250 PMCID: PMC4851211 DOI: 10.1038/leusup.2012.6

Abstract

Acute lymphoblastic leukemia (ALL) in adults is currently associated with an overall survival rate of around 40% at 5 years. This is an unsatisfactory result that makes it imperative to dissect further the biology of the disease in order to identify highly specific therapeutic targets to implement selectively the cure rate. The recognition of discrete ALL subsets followed by the application of risk-oriented therapies has been a major achievement over the past 30 years.

Keywords: acute lymphoblastic leukemia; risk classification; treatment strategy

References

  1. Leukemia. 2010 Mar;24(3):521-35 - PubMed
  2. J Clin Oncol. 2011 Jun 20;29(18):2493-8 - PubMed
  3. J Clin Oncol. 2009 Feb 20;27(6):911-8 - PubMed
  4. Blood. 2006 Feb 1;107(3):1116-23 - PubMed
  5. Haematologica. 2012 Apr;97(4):568-71 - PubMed
  6. Blood. 2008 Feb 15;111(4):1827-33 - PubMed
  7. Blood. 2009 Apr 30;113(18):4153-62 - PubMed
  8. J Clin Oncol. 2011 Feb 10;29(5):532-43 - PubMed
  9. Blood. 2011 Sep 29;118(13):3504-11 - PubMed

Publication Types